** Shares of medical device maker Dexcom DXCM.O fall 3.9% to $74.82 premarket
** Late on Friday, DXCM said it had received a warning letter from the U.S. FDA following inspections of its two manufacturing facilities in San Diego, California and Mesa, Arizona
** Company said it has already submitted responses to the so-called "Form 483" and is currently preparing a written response
** A Form 483 is an agency report that includes "observations" made by FDA inspectors regarding practices or conditions they find "objectionable
** Stock has fallen 41.6% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。